Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Next-Gen Oncology Devices and Solutions Market to Double by 2030, Reaching Over $38 Billion

globenewswire.com
JNJ Mentioned as a dominant player in the growing oncology devices and solutions market, but no specific product or performance details are provided. MRK Listed as a major player in the expanding oncology devices and solutions market, without specific details on its contributions or performance. GEHC Included as a key company in the oncology devices and solutions market, but the article does not offer specific insights into its role or performance. HOLX The acquisition of Endomag is highlighted as enhancing its breast cancer surgery portfolio, indicating a positive strategic move in a growing market.

Next-Gen Oncology Devices and Solutions Market to Double by 2030, Reaching Over $38 Billion Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Next-Generation Oncology Devices and Solutions Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The next-generation oncology devices and solutions market is set to experience substantial growth, expanding from $16.41 billion in 2025 to $19.46 billion in 2026, with a CAGR of 18.6%. Factors driving this growth include the rising global cancer incidence, enhanced molecular diagnostics, advanced oncology tools, and increased adoption of targeted therapies.

By 2030, the market is projected to reach $38.19 billion, with a CAGR of 18.4%, fueled by demand for personalized cancer treatments, investments in genomic diagnostics, early screening programs, AI integration, and biomarker management advancements.

The cancer prevalence surge, primarily due to aging populations, underscores the need for next-generation oncology solutions, enabling earlier detection and more accurate diagnoses. For instance, in 2024, the American Cancer Society predicted over 611,000 cancer-related deaths annually in the U.S., highlighting the urgent demand for advanced oncology devices.

Innovation remains at the forefront, with companies like Integrated DNA Technologies (IDT) launching the xGen Hybridization and Wash v3 Kit in April 2025 to expedite cancer research. This kit streamlines next-generation sequencing (NGS) workflows, reducing hybridization time and improving automation readiness. Similarly, Hologic's 2024 acquisition of Endomag enhances its breast cancer surgery portfolio, focusing on precise cancer care.

The market is dominated by major players, including Johnson & Johnson Services Inc., Siemens AG, Merck & Co. Inc., and others, with North America leading the market regionally in 2025. Coverage extends across Asia-Pacific, Europe, South America, and more, with specific insights into countries such as China, India, Japan, and Germany.

Reasons to Purchase:

Report Scope:

Key Companies Mentioned: Johnson & Johnson, Siemens, Merck, Novartis, GE HealthCare, and others.

Countries: Includes major markets like USA, China, Germany, and emerging ones like Taiwan, Indonesia.

Regions: Asia-Pacific, Europe, North America, etc.

Data Features: Provides a five-year historical and ten-year forecast, with data in Word, PDF, and an interactive Excel dashboard.

Key Attributes

The companies featured in this Next-Generation Oncology Devices and Solutions market report include:

For more information about this report visit https://www.researchandmarkets.com/r/eapwd3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment